Molecule intelOpportunity: Moderate0

Nebuliser

7 brands · 4 companies · product forms

Opportunity snapshot

Launch attractiveness
46
Market saturation
11
Price room
100
Regulatory risk
0
7
brands
4
companies
Rs 632.23
median price
3
price points
36.41x
price spread
90
confidence %

Who competes here

Top companies by brand count — concentrated market · leader share 43%

Price room

Across observed sources and strengths
CheapestRs 312.15
MedianRs 632.23
Most expensiveRs 11,364.67
Spread36.41×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 36.41x across 3 trusted points (Rs 312.15-11364.67). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 9 live products for Nebuliser — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(12) + 25% price-variation(100) + 20% low-competition(89) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

4 canonical companies and 7 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 36.41x across 3 trusted points (Rs 312.15-11364.67). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Reduced by: no ATC code.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.